Home > Boards > US OTC > Medical - Healthcare > STARPHARMA (SPHRY)

Starpharma raising $23m for clinical programs

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Michael Scofield Member Profile
 
Followed By 14
Posts 894
Boards Moderated 0
Alias Born 04/24/09
160x600 placeholder
Michael Scofield   Monday, 09/22/14 11:56:54 AM
Re: None
Post # of 145 
Starpharma raising $23m for clinical programs

Starpharma (ASX:SPL) has raised $18 million, through a placement, to help fund the company’s clinical and commercialisation programs. The company plans to follow this up with an up-to $5 million share purchase plan at $0.65 per share. Part of the proceeds from the capital raising will be used to support the completion of phase III trials of Starpharma’s VivaGel for the prevention of recurrent bacterial vaginosis (BV), and regulatory and commercialisation activities for VivaGel for symptomatic relief of BV. Funds will also be used to help advance chemotherapeutic candidate DEP docetaxel from phase I into phase II trials, as well as to advance other development programs, the company said. Starpharma CEO Dr Jackie Fairley said the capital raising has attracted “strong interest” from the company’s existing institutional shareholders. “We also have welcomed several new local and international funds as shareholders in Starpharma for the first time,” she said. The company last month revealed that spending on its development programs had reduced its cash position to $24 million as of the end of FY14, from $33.8 million at the end of the prior financial year. Starpharma (ASX:SPL) shares were trading 6.34% lower at $0.665 as of around 2.30 pm on Monday.

Keep Posting, They're Watching.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist